Arcturus Therapeutics vs uniQure
ARCT and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARCT and QURE compare
uniQure is the larger company, worth 6.4 times as much as Arcturus Therapeutics ($1.4B against $227M).
uniQure grew revenue faster over the last twelve months (30.2% versus −76.0% for Arcturus Therapeutics).
Arcturus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −318% compared with −1351% at uniQure.
Arcturus Therapeutics scores higher on the StockData Score (9 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARCT | QURE |
|---|---|---|
| Size and price | ||
| Market cap | $227M | $1.4B |
| Share price | $7.97 | $20.78 |
| Change, 1 year | 9.6% | −30.5% |
| Change, 5 years | −80.0% | −27.9% |
| Beta (5Y) | 2.03 | 3.14 |
| Employees | 111 | 221 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.7× (better) | 77.2× |
| P/B | 1.3× (better) | 4.4× |
| FCF yield | −32.1% | −11.2% (better) |
| Fair value | $8.83 | $6.42 |
| Margin of safety | 9.8% (better) | −224% |
| Growth | ||
| Revenue growth (TTM) | −76.0% | 30.2% (better) |
| Revenue growth, 5Y average | 53.8% (better) | −15.6% |
| Profitability | ||
| Gross margin | – | 92.5% |
| Operating margin | −348% (better) | −1072% |
| Net margin | −318% (better) | −1351% |
| FCF margin | −248% (better) | −865% |
| Return on equity | −46.3% (better) | −158% |
| Return on invested capital | −1084% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.15 (better) |
| Interest coverage | – | −3.4× |
| Current ratio | 5.88 | 10.01 (better) |
| Altman Z-score | −1.44 | −0.51 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 87.9% | 96.0% |
| Held by insiders | 8.1% | 2.1% |
| Insider net buying, 12 months | – | −$20.2M |
| Short interest, % of float | 20.7% | 12.5% |
Go deeper
- ARCT stock overview
- ARCT income statement
- ARCT valuation and score
- QURE stock overview
- QURE income statement
- QURE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.